Laser still the mainstay of macular oedema treatment

The parameters of laser photocoagulation have evolved in recent clinical studies

Laser still the mainstay of macular oedema treatment
Dermot McGrath
Dermot McGrath
Published: Monday, June 12, 2017

David Pelayes MD
While the introduction of anti-VEGF therapies is transforming the clinical management of diabetic macular oedema (DME), focal laser photocoagulation still remains the gold standard in the initial treatment of the disease, according to David Pelayes MD. "We now have more options thanks to anti-VEGF therapies, but focal laser is not going to disappear from our treatment arsenal. Reducing the side effects and improving the safety and efficacy of the therapy are some of the central aims of contemporary laser photocoagulation," he told delegates attending the European Society of Ophthalmology (SOE) 2017 Congress in Barcelona, Spain. Dr Pelayes, Full Professor of Ophthalmology, Buenos Aires University, Argentina, and Full Professor of Ophthalmology, Maimonides University, noted that the parameters of laser photocoagulation have evolved in recent clinical studies by incorporating shorter pulse durations and lower laser energy. "Clinical trials have demonstrated that lower energy can reduce side effects and risks while effectively alleviating DME," he said.
Clinical trials have demonstrated that lower energy can reduce side effects and risks while effectively alleviating DME
The general macular settings for the laser now include an exposure time of 10 to 20 milliseconds, resulting in sharply decreased energy density and thermal diffusion, he explained. "Furthermore, studies have shown that the retinal photocoagulation induced by 10 to 30 ms exposure time can stimulate inner retinal healing responses and is associated with less destructive effects than traditional methods," he said.
Tags: macular oedema, retina
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...